克里唑替尼盐酸 T8399

Product Introduction
Bioactivity


英文名: Crizotinib hydrochloride

描述: Crizotinib hydrochloride (PF-02341066 hydrochloride) 是一种可口服的，具有选择性的 ATP 竞争性双 ALK 和 c-Met 抑制剂。它也是 ROS 原癌基因 1 抑制剂，可抑制肿瘤生长。在细胞的实验中，它抑制 NPM-ALK 的酪氨酸磷酸化和 c-Met 的酪氨酸磷酸化。

体外活性: Crizotinib hydrochloride(PF-2341066)potently inhibited NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells (mean IC(50) value, 24 nmol/L).?In biochemical and cellular screens, PF-2341066 was shown to be selective for c-Met and ALK at pharmacologically relevant concentrations across a panel of >120 diverse kinases.?PF-2341066 potently inhibited cell proliferation, which was associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells (IC(50) values, approximately 30 nmol/L) but not ALK-negative lymphoma cells[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 4.9 mg/mL (10.07 mM)
H2O : 50 mg/mL (102.71 mM)


关键字: Crizotinib Hydrochloride | PF02341066 Hydrochloride | CD246 | PF-02341066 | ROS Kinase | PF 02341066 Hydrochloride | Autophagy | ALK tyrosine kinase receptor | Anaplastic lymphoma kinase (ALK) | PF02341066 | Crizotinib hydrochloride | c-Met/HGFR | PF 02341066 | Crizotinib | Cluster of differentiation 246 | Inhibitor | PF-02341066 Hydrochloride | inhibit | Anaplastic lymphoma kinase

相关产品: APG-2449 | ROS kinases-IN-1 | ROS-generating agent 1 | Methyl 12-methyltridecanoate | Entrectinib | Repotrectinib | Salvigenin | Uniconazole | Taletrectinib free base | F-1

相关库: Drug Repurposing Compound Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Approved Drug Library | Tyrosine Kinase Inhibitor Library | EMA Approved Drug Library

克里唑替尼盐酸 T8399信息由TargetMol中国为您提供，如您想了解更多关于克里唑替尼盐酸 T8399报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途